News headlines about Allergan PLC. (NYSE:AGN) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Allergan PLC. earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.2955464256015 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:

A number of equities analysts have weighed in on the company. Argus reiterated a “buy” rating and set a $280.00 price objective on shares of Allergan PLC. in a research note on Monday. UBS AG reiterated an “outperform” rating and set a $275.00 price objective on shares of Allergan PLC. in a research note on Wednesday, August 9th. Deutsche Bank AG reiterated a “buy” rating and set a $278.00 price objective (up previously from $273.00) on shares of Allergan PLC. in a research note on Wednesday, August 9th. BidaskClub lowered Allergan PLC. from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Finally, Wells Fargo & Company reiterated an “outperform” rating and set a $280.00 price objective (up previously from $270.00) on shares of Allergan PLC. in a research note on Wednesday, August 9th. Eight research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Allergan PLC. presently has an average rating of “Buy” and a consensus price target of $275.49.

Allergan PLC. (AGN) traded down 0.10% during midday trading on Monday, reaching $232.64. The company had a trading volume of 1,441,849 shares. The firm’s 50 day moving average is $245.54 and its 200 day moving average is $238.65. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80. The stock has a market capitalization of $77.77 billion, a PE ratio of 7.09 and a beta of 1.16.

Allergan PLC. (NYSE:AGN) last issued its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. During the same period last year, the company posted $3.35 earnings per share. The firm’s quarterly revenue was up 8.8% compared to the same quarter last year. On average, equities analysts anticipate that Allergan PLC. will post $16.27 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Friday, August 18th will be issued a $0.70 dividend. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a yield of 1.20%. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.95%.

In other Allergan PLC. news, Director Nesli Basgoz sold 1,889 shares of the stock in a transaction dated Thursday, May 18th. The shares were sold at an average price of $220.45, for a total value of $416,430.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.36% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Allergan PLC. (NYSE:AGN) Earns Media Sentiment Score of 0.24” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Insider Buying and Selling by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.